Mass spectrometric analysis of protein–ligand interactions

Kentaro Ishii¹, Masanori Noda² and Susumu Uchiyama¹,²

¹Okazaki Institute for Integrative Bioscience, National Institutes of Natural Sciences, Okazaki, Aichi 444-8787, Japan
²Department of Biotechnology, Graduate School of Engineering, Osaka University, Suita, Osaka 565-0871, Japan

Received January 12, 2016; accepted February 16, 2016

The interactions of small molecules with proteins (protein–ligand interactions) mediate various biological phenomena including signal transduction and protein transcription and translation. Synthetic compounds such as drugs can also bind to target proteins, leading to the inhibition of protein–ligand interactions. These interactions typically accompany association–dissociation equilibrium according to the free energy difference between free and bound states; therefore, the quantitative biophysical analysis of the interactions, which uncovers the stoichiometry and dissociation constant, is important for understanding biological reactions as well as for rational drug development. Mass spectrometry (MS) has been used to determine the precise molecular masses of molecules. Recent advancements in MS enable us to determine the molecular masses of protein–ligand complexes without disrupting the non-covalent interactions through the gentle desolvation of the complexes by increasing the vacuum pressure of a chamber in a mass spectrometer. This method is called MS under non-denaturing conditions or native MS and allows the unambiguous determination of protein–ligand interactions. Under a few assumptions, MS has also been applied to determine the dissociation constants for protein–ligand interactions. The structural information of a protein–ligand interaction, such as the location of the interaction and conformational change in a protein, can also be analyzed using hydrogen/deuterium exchange MS. In this paper, we briefly describe the history, principle, and recent applications of MS for the study of protein–ligand interactions.

Key words: Mass spectrometry, dissociation constant (K_D), affinity, hydrogen/deuterium exchange mass spectrometry, drug screening

The analysis of protein–ligand interactions is important for understanding various biological phenomena and drug development. The physico-chemical parameters that characterize protein–ligand interactions are stoichiometry and dissociation constant (K_D), from which the free energy difference of the interaction is estimated. Several biophysical methods for the assessment of protein–ligand interactions exist, including surface plasmon resonance (SPR), capillary electrophoresis, isothermal titration calorimetry (ITC), and mass spectrometry (MS). Each method has both advantages and disadvantages; thus, one must select the appropriate method based on the purpose of the measurement. In the past two decades, MS has been used widely in the field of biological research to identify and quantify metabolites and proteins; however, under the conditions of conventional MS, biological substances dissociate into individual molecules during ionization or desolvation; therefore, protein–ligand interactions are rarely observed. Meanwhile, recent advances in mass spectrometry (MS) enable us to know the molecular masses of protein ligand complexes without a disruption of non-covalent interactions. This method is called MS under non-denaturing conditions or native MS. Thus, one can know the stoichiometry of a protein–ligand interaction unambiguously. Also, attempts to determine the dissociation constant of a protein–ligand interaction have been made by MS under a few assumptions. The location of the interaction and conformational change in a protein can be analyzed by hydrogen/deuterium exchange MS. This article describes how MS is effective in the study on protein–ligand interactions.
I. Early MS studies of protein–ligand interactions

The earliest MS study of protein–ligand interactions focused on the interaction between cytoplasmic receptor FK506 binding protein (FKBP; 11,812 Da) and immunosuppressant FK506 (804 Da) (Table 1) [5]. The 1:1 complex of FKBP:FK506 was observed in 10 mM ammonium acetate at pH 7.5. The authors observed the protein–ligand interactions by electrospray ionization (ESI) MS. Katta and Chait reported the observation of the hemoglobin complex [6], and we recently reported three cases of protein–ligand interactions: nuclear receptor peroxisome proliferator–activated receptor γ (PPARγ)–endocrine disruptors [7], protein tyrosine phosphatase PTPRZ–inhibitor [8], and HIV–1 reverse transcriptase–drugs [9]. Typically, the MS study of protein–ligand complexes requires the modification of various components and conditions within a mass spectrometer. Higher pressures in the front end of the instrument are required to focus and decelerate the high-m/z ions of protein–ligand complexes. In addition, low-frequency quadrupoles might be required for the selection and/or transmission of the ions. MS is performed in vacuum (Fig. 2), and the hydrogen bonds, electrostatic interactions, and van der Waals forces are strengthened or unchanged by the transfer from the solution to the gas phase, while hydrophobic interactions are weakened [10]. Thus, protein–ligand complexes formed mainly through the former forces are retained, while those formed primarily through the latter forces are prone to be disrupted during MS.

II. Parameters obtained from MS studies of protein–ligand interactions

Stoichiometry

We can determine the stoichiometry of a protein–ligand complex from the mass shift. Figure 3 shows the ESI mass spectra of a nuclear receptor, PPARγ, with triphenyltin of

Table 1  Protein–ligand interactions measured by MS under non-denaturing conditions

| Proteins (peptides)                  | Ligands       | \( K_{D} \) (μM) | References |
|--------------------------------------|---------------|------------------|------------|
| FK506 binding protein                | FK506 (drug)  | 0.0004           | [5]        |
| Globin                               | Heme          |                  | [6]        |
| Vancomycin\textsuperscript{b}        | Peptide       | 1–90             | [13]       |
| OppA                                 | Peptide       | 56–2,900         | [22]       |
| Replication terminator protein       | DNA           | \( \leq 0.002 \) | [23]       |
| Chorismate mutase                    | Inhibitor     | 1.7              | [24]       |
| RNase A                              | 2’-CMP\textsuperscript{c} | 2.0            | [25]       |
| hGHbp\textsuperscript{d}             | Compound\textsuperscript{e} | 0.76            | [14]       |
| Beta-peptide                         | Zinc          | 20               | [26]       |
| Antigen binding fragment             | Hexasaccharide ligand | 6.3            | [27]       |
| Norovirus P domain                   | HBGA oligosaccharide | 333–2,778       | [28]       |
| ABC transporter\textsuperscript{f}   | Drug and lipid|                  | [21]       |

\textsuperscript{a} methods except for MS, \textsuperscript{b} glycopeptide, \textsuperscript{c} cytidine 2’-monophosphate, \textsuperscript{d} the soluble domain of human growth hormone receptor, \textsuperscript{e} neutral nonpolar compounds from the compound collection at Biovitrum AB, \textsuperscript{f} ATP-binding cassette transporter P-glycoprotein.
endocrine disruptors [7]. Under denatured conditions obtained by, for example, adding formic acid to the sample solution, a 31,370.6 Da molecule corresponding to PPARγ is observed (Fig. 3A and B); under non-denaturing conditions, a 31,718.8 Da molecule corresponding to the PPARγ–triphenyltin complex is observed (Fig. 3C). This mass shift corresponds to the mass of triphenyltin. As another example, Figure 4 shows the ESI mass spectra of protein tyrosine phosphatase PTPRZ in the absence or presence of inhibitor SCB4380. In the absence of the inhibitor, the molecule with a mass of 70985.3 Da corresponding to PTPRZ is observed (Fig. 4A). After the addition of the inhibitor, a molecule with a mass of 70451.2 Da corresponding to the mass of the 1:1 complex is observed, and the relative amount of the complex increases dose-dependently (Fig. 4B–E).

Furthermore, we can directly identify the composition of the complex by using MS/MS when a stable and strong MS signal is acquired. As shown in Figure 5, the complex molecule is selectively dissociated into its components, the protein and ligand, by MS/MS using collision-induced dissociation (CID) within the mass spectrometer, and their masses can then be precisely determined.

**Dissociation constant**

The $K_D$ of a protein–ligand interaction can be estimated based on a dose-response or competition experiment. $K_D$ values ranging from 0.002 to 2,778 μM have been reported based on MS experiments (Table 1). The dose-response experiment can be performed by fixing the protein concentration while varying the ligand concentration, or vice versa [11]. The signal responses of the protein–ligand complex and the free protein in the mass spectra are not always the same, because the ion emission efficiency, transmission efficiency, and detector efficiency may be different between the complex and the free protein. To overcome this problem, Gabelica et al. introduced the response factor $R$, which is defined as [12]

$$R = \frac{PL}{P} = \frac{[PL]_eq}{[P]_eq}$$

(Eq. 1)

where $P$ and $PL$ indicate the signal intensities of a ligand-free protein and a protein–ligand complex, respectively, and $[P]_eq$ and $[PL]_eq$ indicate the concentrations of the ligand-free protein and protein–ligand complex, respectively, at equilibrium. The two variables, $K_D$ and $R$, are estimated based on the nonlinear fitting of an experimentally observed dose-response curve using the following equation (Eq. 2):

$$R/(R+1) = \frac{[P]_0}{K_D} + \frac{[L]_0}{K_D} - \sqrt{\left( \frac{[P]_0}{K_D} \right)^2 + \frac{4[L]_0}{K_D^2}}$$

(Eq. 2)

where $[P]_0$ and $[L]_0$ indicate the initial concentrations of protein and ligand, respectively. An alternative method to determine $K_D$ is via a competition experiment in which an equimolar mixture of several ligands is added to a protein in solution [13,14]. In this analysis, the $K_D$ values for the interactions between a protein and several different molecules can be determined simultaneously, assuming that the ion
complex are expressed by the following equation:

\[ [P_i] = \frac{P + PL_1 + PL_2 + PL_3}{P + [P_i]_{0}} \]  

(Eq. 3)

where \([P_i]\) refers to the concentration of the protein in different forms, \([P_i]_{0}\) is the initial concentration of protein–ligand complex.

Figure 3 Mass spectra of the PPARγ–ligand binding domain complex with triphenyltin (TPT) under non-denaturing conditions. The PPARγ–ligand binding domain forms a complex with TPT in a 1:1 molar ratio (A–C). The mass patterns after the addition of aliquots of formic acid (A, 3%; B, 1%; C, 0%) to the complex indicate that the dissociation of the interaction is caused by the unfolding of the PPARγ–ligand binding domain (refer to [7]).

Figure 4 One-to-one binding of the inhibitor SCB4380 to protein tyrosine phosphatase PTPRZ. MS spectra of PTPRZ in the presence of the inhibitor (A–E). PTPRZ was mixed with the inhibitor at the indicated concentrations, and inhibitor binding to PTPRZ was monitored by MS under non-denaturing conditions. Peaks corresponding to PTPRZ and the 1:1 PTPRZ-inhibitor complex are indicated by blue and red dots (with charge states), respectively (modified from [8]).
changes and interaction sites between proteins and ligands by monitoring the exchange reaction from hydrogen to deuterium of the amide proton in a protein in D2O [15]. As shown in Figure 7, the amide hydrogen atoms in the peptides that are exposed on the protein’s surface but not involved in the secondary structure formation or the protein–ligand interactions exchange to deuterium rapidly (high H/D exchange rate), while those located inside the protein or at the sites of protein–ligand interaction are slowly exchanged (low H/D exchange rate). An HDX-MS experiment is carried out as follows: (i) a protein or protein–ligand complex is placed into deuterium buffer to start the exchange reaction, (ii) the exchange reaction is quenched by lowering the pH and temperature, (iii) the protein is digested into peptides through a pepsin-immobilized column, (iv) the peptide fragments are separated by reverse-phase liquid chromatography, and (v) the separated peptides are analyzed by MS and MS/MS. In order to minimize the back exchange reaction of amide deuterium, chromatographic separations are carried out at temperatures close to freezing temperature. In the recent HDX-MS studies of protein–ligand interactions, the exchange rates of the digested peptides were compared to those of the free protein and protein–ligand complex because this method is less influenced by the changes in experimental conditions between the free protein and protein–ligand complex; thus, this method can quickly provide reliable information on the interaction, although the absolute exchange rate of each peptide is difficult to estimate. In HDX-MS, there is essentially no limitation on the molecular weight of the target protein, and elaborate procedures such as crystallization or isotope labeling are not necessary. Furthermore, it is usually possible to clarify the interaction site within a short period compared to X-ray crystallography or NMR spectroscopy. Here, we introduce examples of complexes, and P, PL1, PL2, and PL3 are the signal intensities of the free protein and those of the three complexes, respectively.

The $K_D$ values are expressed by the following equation:

$$K_{PL1} = \frac{[PL_1]}{[P][L_1]} = \frac{[PL_1]}{[P][P] + [PL_2] + [PL_3]} \quad (\text{Eq. 4})$$

Thus, the $K_D$ values are estimated by substituting the protein and protein–ligand complex concentrations into Eq. 4. Good agreements were confirmed between the $K_D$ values derived from MS data and the published values that were determined by other methods [13].

**Binding site**

We can determine the binding sites of protein–ligand interactions from HDX-MS. HDX-MS reveals the structural

**Figure 5** Detection of components of a protein–ligand complex using MS/MS. The complex of the PPARγ–ligand binding domain and compound F (m/z 2,650; red arrow) were dissociated into the compound F (yellow arrow) and the PPARγ–ligand binding domain (green and blue arrows) by MS/MS.

**Figure 6** Mass spectrum for a competition experiment. P, PL1, PL2, and PL3 are the peaks corresponding to the ligand-free protein, protein–ligand complex, protein–ligand complex, and protein–ligand complex, respectively.
Note that the interaction sites discussed above were determined at resolutions of 5–20 amino acids; determination at higher resolution is difficult using typical MS/MS fragmentation methods such as CID because of the scrambling of amide hydrogen and deuterium during fragmentation. On the other hand, it is now possible to identify binding sites at a resolution of one amino acid residue using electron transfer dissociation as the MS/MS fragmentation method alternative to CID. For example, Landgraf et al. reported that two Gln residues located at the helix 3 of PPARγ are directly involved in its interaction with rosiglitazone [18].

III. Drug screening using MS

Although no report on high-throughput drug screening using MS under non-denaturing conditions has been published to date, MS shows potential for this application. Bovet et al. reported the interactions of an estrogen receptor with low-molecular-weight compounds [19]. They compared the affinities of estrogen, the compounds, an endocrine disrupter, and a phyto-hormone for the estrogen receptor using MS competition experiments and showed that the rank order of the estimated affinities are consistent with their reported $K_d$ values. We recently examined the interaction of the human immunodeficiency virus-1 reverse transcriptase (HIV-1 RT) with drugs in different generations by MS under non-denaturing conditions [9]. The half-concentrations of

---

**Figure 7** Schematic presentation of hydrogen/deuterium exchange mass spectrometry (HDX-MS). (A) An experimental flowchart of HDX-MS for protein–ligand interactions. (i) A free protein or protein–ligand complex is placed into deuterium buffer to start the exchange reaction, (ii) the exchange reaction is quenched by lowering the pH and temperature, (iii) the protein is digested into peptides through the pepsin-immobilized column, (iv) the peptide fragments are separated by ultra-high performance reverse-phase liquid chromatography (UHPLC), and (v) the separated peptides are analyzed by MS and MS/MS. (B) Amide hydrogen in a peptide that is exposed to solvent and not involved in the secondary formation is rapidly exchanged with deuterium, leading to a mass increase by the H/D exchange reaction (left), while peptides located at the site of protein–ligand interaction show slow or no exchange during the observation period (right).

---

Protein–ligand interactions studied by HDX-MS. Griffin and colleagues used HDX-MS to study the interactions between PPARγ and various ligands; they revealed not only the region of ligand binding (helix 3) but also the ligand-induced change in the dynamics of helix 12 of the ligand-binding domain [16]. In this case, HDX-MS was complementary to X-ray crystallography because the ligand-induced changes in the dynamics of helix 12 of PPARγ captured by HDX-MS were not observed in the crystal structural analyses of free PPARγ and PPARγ–ligand complexes. Another example of a change in protein dynamics upon ligand binding was reported for the interaction of protein kinase A with cAMP by Hamuro et al. [17]. We reported an HDX-MS study to reveal the site of interaction between PTPRZ and the inhibitor SCB4380 (Fig. 8). The use of MS under non-denaturing conditions clarified that the inhibitor SCB4380 binds to PTPRZ in 1:1 stoichiometry. Ninety peptides commonly identified in PTPRZ and the PTPRZ-inhibitor complex were analyzed for the assessment of the H/D exchange rate. By incubating PP-A with the inhibitor, the HDX rate of PTPRZ was significantly decreased in two peptide fragments. When compared to the control without ligand incubation, the incubated peptides contained the catalytic residues of PTPRZ. On the other hand, no changes were observed in the HDX rates of the peptides from other regions. These results strongly suggest that the inhibitor specifically binds to the catalytic site of PTPRZ, thereby inhibiting its catalytic activity. Note that the interaction sites discussed above were determined at resolutions of 5–20 amino acids; determination at higher resolution is difficult using typical MS/MS fragmentation methods such as CID because of the scrambling of amide hydrogen and deuterium during fragmentation. On the other hand, it is now possible to identify binding sites at a resolution of one amino acid residue using electron transfer dissociation as the MS/MS fragmentation method alternative to CID. For example, Landgraf et al. reported that two Gln residues located at the helix 3 of PPARγ are directly involved in its interaction with rosiglitazone [18].
proteins; for example, Robinson’s group recently reported the interaction of a drug with a membrane protein.

**Conclusion**

MS is now one of the most powerful and efficient methods for studying protein–ligand interactions. In particular, interaction stoichiometry can be precisely and quickly determined by MS under non-denaturing conditions. Several studies have shown that the $K_D$ of a protein–ligand interaction can also be estimated under a few assumptions. However, while the relative affinity of a protein–ligand interaction can be accurately estimated by MS under non-denaturing conditions, the absolute $K_D$ should be validated using orthogonal methods.
methods such as SPR and ITC. When the interaction site is determined using HDX-MS, validation of the identified site is highly recommended using different methods. Interaction analysis using proteins with the replacement of amino acids located at the identified sites and/or docking simulation analysis are methods usable for such a validation.

Acknowledgements

This work was supported by the Okazaki ORION project and by the Joint Studies Program (2014–2015) in the Okazaki BIO-NEXT project of the Okazaki Institute for Integrative Bioscience. The authors would like to thank Enago (www.enago.jp) for the English language review.

Conflicts of interest

K. I., M. N., and S. U. declare that they have no conflict of interest.

Author contributions

All authors wrote and reviewed the manuscript.

References

[1] Hernandez, H. & Robinson, C. V. Determining the stoichiometry and interactions of macromolecular assemblies from mass spectrometry. Nat. Protoc. 2, 715–726 (2007).
[2] Zhang, J., Chalmers, M. J., Stayrook, K. R., Burris, L. L., Wang, Y., Busby, S. A., et al. DNA binding alters coactivator interaction surfaces of the intact VDR-RXR complex. Nat. Struct. Mol. Biol. 18, 556–563 (2011).
[3] Stocks, B. B. & Konermann, L. Time-dependent changes in side-chain solvent accessibility during cytochrome c folding probed by pulsed oxidative labeling and mass spectrometry. J. Mol. Biol. 398, 362–373 (2010).
[4] Herzog, F., Kahraman, A., Boehringer, D., Mak, R., Bracher, A., Walzthoeni, T., et al. Structural probing of a protein phosphatase 2A network by chemical cross-linking and mass spectrometry. Science 337, 1348–1352 (2012).
[5] Gannem, B., Li, Y. & Henten, J. Detection of noncovalent receptor ligand complexes by mass-spectrometry. J. Am. Chem. Soc. 113, 6294–6296 (1991).
[6] Katta, V. & Chait, B. Observation of the heme globin complex in native myoglobin by electrospray-ionization mass-spectrometry. J. Am. Chem. Soc. 113, 8534–8535 (1991).
[7] Harada, S., Hiromori, Y., Nakamura, S., Kawahara, K., Fukakusa, S., Maruno, T., et al. Structural basis for PPARγ transactivation by endocrine-disrupting organotin compounds. Sci. Rep. 5, 8520 (2015).
[8] Fujikawa, A., Nagahira, A., Sugawara, H., Ishii, K., Imajo, S., Matsumoto, M., et al. Small-molecule inhibition of PTBPRZ reduces tumor growth in a rat model of glioblastoma. Sci. Rep. 6, 20473 (2016).
[9] Thammaporn, R., Ishii, K., Yagi-Utsumi, M., Uchiyama, S., Hannonguea, S. & Kato, K. Mass spectrometric characterization of HIV-1 reverse transcriptase interactions with non-nucleoside reverse transcriptase inhibitors. Bio. Pharm. Bull. (in press).
[10] Daniel, J., Friess, S., Rajagopalan, S., Wendi, S. & Zenobi, R. Quantitative determination of noncovalent binding interactions using soft ionization mass spectrometry. Int. J. Mass Spectrom. 216, 1–27 (2002).
[11] Sannes-Lowery, K., Griffey, R. & Hofstadler, S. Measuring dissociation constants of RNA and aminoglycoside antibiotics by electrospray ionization mass spectrometry. Anal. Biochem. 280, 264–271 (2000).
[12] Gabela, V., Galic, N., Rosu, F., Houssier, C. & De Pauw, E. Influence of response factors on determining equilibrium association constants of non-covalent complexes by electrospray ionization mass spectrometry. J. Mass Spectrom. 38, 491–501 (2003).
[13] Jorgensen, T., Ropstorf, P. & Heck, A. Direct determination of solution binding constants for noncovalent complexes between bacterial cell wall peptide analogues and vancomycin group antibiotics by electrospray ionization mass spectrometry. Anal. Chem. 70, 4427–4432 (1998).
[14] Tjernberg, A., Carnö, S., Oliv, F., Benkestock, K., Elander, P. O., Griffiths, W. J., et al. Determination of dissociation constants for protein-ligand complexes by electrospray ionization mass spectrometry. Anal. Chem. 76, 4325–4331 (2004).
[15] Zhang, J., Chalmers, M., Stayrook, K., Burris, L., Garcia-Ordonez, R., Pascual, B., et al. Hydrogen/deuterium exchange reveals distinct agonist/partial agonist receptor dynamics within vitamin D receptor/retinoid X receptor heterodimer. Structure 18, 1332–1341 (2010).
[16] Bruning, J. B., Chalmers, M. J., Prasad, S., Busby, S. A., Kamenecka, T. M., He, Y., et al. Partial agonists activate PPARgamma using a helix 12 independent mechanism. Structure 15, 1258–1271 (2007).
[17] Hamuro, Y., Anand, G. S., Kim, J. S., Juliano, C., Stranz, D. D., Taylor, S. S., et al. Mapping intersubunit interactions of the regulatory subunit (R1alpha) in the type I holoenzyme of protein kinase A by amide hydrogen/deuterium exchange mass spectrometry (DXMS). J. Mol. Biol. 340, 1185–1196 (2004).
[18] Landgraf, R., Chalmers, M. & Griffin, P. Automated hydrogen/deuterium exchange electron transfer dissociation high resolution mass spectrometry measured at single-amide resolution. J. Am. Soc. Mass Spectrom. 23, 301–309 (2012).
[19] Bovet, C., Wirtzmann, A., Eiler, S., Granger, F., Ruff, M., Gerrits, B., et al. Estrogen receptor-ligand complexes mea-
sured by chip-based nanoelectrospray mass spectrometry: an approach for the screening of endocrine disruptors. *Protein Sci.* **16**, 938–946 (2007).

[20] Zhou, M., Morgner, N., Barrera, N. P., Politis, A., Isaacson, S. C., Mata-Vinković, D., *et al.* Mass spectrometry of intact V-type ATPases reveals bound lipids and the effects of nucleotide binding. *Science* **334**, 380–385 (2011).

[21] Marcoux, J., Wang, S. C., Politis, A., Reading, E., Ma, J., Biggin, P. C., *et al.* Mass spectrometry reveals synergistic effects of nucleotides, lipids, and drugs binding to a multidrug resistance efflux pump. *Proc. Natl. Acad. Sci. USA* **110**, 9704–9709 (2013).

[22] Rostom, A., Tame, J., Ladbury, J. & Robinson, C. Specificity and interactions of the protein OppA: partitioning solvent binding effects using mass spectrometry. *J. Mol. Biol.* **296**, 269–279 (2000).

[23] Kapur, A., Beck, J., Brown, S., Dixon, N. & Sheil, M. Use of electrospray ionization mass spectrometry to study binding interactions between a replication terminator protein and DNA. *Protein Sci.* **11**, 147–157 (2002).

[24] Wendt, S., McCombie, G., Daniel, J., Kienhofer, A., Hilvert, D. & Zenobi, R. Quantitative evaluation of noncovalent chorismate mutase-inhibitor binding by ESI-MS. *J. Am. Soc. Mass Spectrom.* **14**, 1470–1476 (2003).

[25] Zhang, S., Van Pelt, C. K. & Wilson, D. B. Quantitative determination of noncovalent binding interactions using automated nanoelectrospray mass spectrometry. *Anal. Chem.* **75**, 3010–3018 (2003).

[26] Wortmann, A., Rossi, F., Lelais, G. & Zenobi, R. Determination of zinc to beta-peptide binding constants with electrospray ionization mass spectrometry. *J. Mass Spectrom.* **40**, 777–784 (2005).

[27] Kito, E., El-Hawiet, A., Schnier, P. & Klassen, J. Reliable determinations of protein-ligand interactions by direct ESI-MS measurements. Are we there yet? *J. Am. Soc. Mass Spectrom.* **23**, 431–441 (2012).

[28] Han, L., Kitov, P., Kito, E., Tan, M., Wang, L., Xia, M., *et al.* Affinities of recombinant norovirus P dimers for human blood group antigens. *Glycobiology* **23**, 276–285 (2013).

[29] Uchiyama, S., Noda, M. & Ishii, K. Analysis of higher order structures of proteins by mass spectrometry. *Seibutsu Butsuri* **55**, 270–273 (2015).

[30] Houde, D., Berkowitz, S. A. & Engen, J. R. The utility of hydrogen/deuterium exchange mass spectrometry in biopharmaceutical comparability studies. *J. Pharm. Sci.* **100**, 2071–2086 (2011).

[31] Silprasit, K., Thammaporn, R., Hannongbua, S. & Choowongkomon, K. Cloning, expression, purification, determining activity of recombinant HIV-1 reverse transcriptase. *Kasetsart J. (Nat. Sci.)* **42**, 231–239 (2008).

[32] Singh, K., Marchand, B., Rai, D., Sharma, B., Michailidis, E., Ryan, E., *et al.* Biochemical mechanism of HIV-1 resistance to rilpivirine. *J. Biol. Chem.* **287**, 38110–38123 (2012).